Historical Valuation
Black Diamond Therapeutics Inc (BDTX) is now in the Fair zone, suggesting that its current forward PS ratio of 13.24 is considered Fairly compared with the five-year average of -3.34. The fair price of Black Diamond Therapeutics Inc (BDTX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.81
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Black Diamond Therapeutics Inc (BDTX) has a current Price-to-Book (P/B) ratio of 1.12. Compared to its 3-year average P/B ratio of 1.50 , the current P/B ratio is approximately -25.23% higher. Relative to its 5-year average P/B ratio of 1.42, the current P/B ratio is about -20.88% higher. Black Diamond Therapeutics Inc (BDTX) has a Forward Free Cash Flow (FCF) yield of approximately 15.05%. Compared to its 3-year average FCF yield of -40.23%, the current FCF yield is approximately -137.40% lower. Relative to its 5-year average FCF yield of -50.88% , the current FCF yield is about -129.57% lower.
P/B
Median3y
1.50
Median5y
1.42
FCF Yield
Median3y
-40.23
Median5y
-50.88
Competitors Valuation Multiple
AI Analysis for BDTX
The average P/S ratio for BDTX competitors is 17.78, providing a benchmark for relative valuation. Black Diamond Therapeutics Inc Corp (BDTX.O) exhibits a P/S ratio of 13.24, which is -25.53% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BDTX
1Y
3Y
5Y
Market capitalization of BDTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BDTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BDTX currently overvalued or undervalued?
Black Diamond Therapeutics Inc (BDTX) is now in the Fair zone, suggesting that its current forward PS ratio of 13.24 is considered Fairly compared with the five-year average of -3.34. The fair price of Black Diamond Therapeutics Inc (BDTX) is between to according to relative valuation methord.
What is Black Diamond Therapeutics Inc (BDTX) fair value?
BDTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Black Diamond Therapeutics Inc (BDTX) is between to according to relative valuation methord.
How does BDTX's valuation metrics compare to the industry average?
The average P/S ratio for BDTX's competitors is 17.78, providing a benchmark for relative valuation. Black Diamond Therapeutics Inc Corp (BDTX) exhibits a P/S ratio of 13.24, which is -25.53% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Black Diamond Therapeutics Inc (BDTX) as of Jan 10 2026?
As of Jan 10 2026, Black Diamond Therapeutics Inc (BDTX) has a P/B ratio of 1.12. This indicates that the market values BDTX at 1.12 times its book value.
What is the current FCF Yield for Black Diamond Therapeutics Inc (BDTX) as of Jan 10 2026?
As of Jan 10 2026, Black Diamond Therapeutics Inc (BDTX) has a FCF Yield of 15.05%. This means that for every dollar of Black Diamond Therapeutics Inc’s market capitalization, the company generates 15.05 cents in free cash flow.
What is the current Forward P/E ratio for Black Diamond Therapeutics Inc (BDTX) as of Jan 10 2026?
As of Jan 10 2026, Black Diamond Therapeutics Inc (BDTX) has a Forward P/E ratio of -4.50. This means the market is willing to pay $-4.50 for every dollar of Black Diamond Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Black Diamond Therapeutics Inc (BDTX) as of Jan 10 2026?
As of Jan 10 2026, Black Diamond Therapeutics Inc (BDTX) has a Forward P/S ratio of 13.24. This means the market is valuing BDTX at $13.24 for every dollar of expected revenue over the next 12 months.